Table 1 Clinicopathologic characteristics of colorectal carcinomas according to acetyl-CoA synthetase-2 expression status

From: Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma

 

Acetyl-CoA synthetase-2-low (n=771)

Acetyl-CoA synthease-2-high (n=335)

P-value

Age, years, median (range)

60.5±11.3

61.5±11.0

0.198a

Sex

  

0.987

 Male

463 (60%)

201 (60%)

 

 Female

308 (40%)

134 (40%)

 

Tumor location

  

0.596

 Proximal colon

193 (25%)

82 (25%)

 

 Distal colon

305 (40%)

124 (37%)

 

 Rectum

273 (35%)

129 (38%)

 

Gross pattern

  

0.003

 Fungating

487 (63%)

242 (72%)

 

 Ulcerative

284 (37%)

93 (28%)

 

T category

  

< 0.001

 1,2

104 (14%)

102 (31%)

 

 3,4

667 (86%)

233 (69%)

 

N category

  

< 0.001

 0

352 (46%)

210 (63%)

 

 1,2

419 (54%)

125 (37%)

 

M category

  

0.001

 0

621 (80%)

298 (89%)

 

 1

150 (20%)

37 (11%)

 

Stage

  

< 0.001

 I, II

328 (43%)

199 (59%)

 

 III, IV

443 (57%)

136 (41%)

 

Differentiation

  

0.007

 Well/moderate

737 (96%)

331 (99%)

 

 Poor

34 (4%)

4 (1%)

 

Tumor budding

  

0.015

 Absent

200 (26%)

111 (33%)

 

 Present

571 (74%)

224 (67%)

 

Luminal necrosis

  

0.439

 Absent

67 (9%)

34 (10%)

 

 Present

704 (91%)

301 (90%)

 

Crohn-like lymphoid reaction

  

0.06

 Absent

645 (84%)

295 (88%)

 

 Present

126 (16%)

40 (12%)

 

Tumor-infiltrating lymphocytes

  

0.119

 Low (<8/HPF)

580 (75%)

237 (71%)

 

 High (≥ \8/HPF)

191 (25%)

98 (29%)

 

Luminal serration

  

0.436

 Absent

738 (96%)

324 (97%)

 

 Present

33 (4%)

11 (3%)

 

Extraglandular mucin

  

0.547

 Absent

676 (88%)

298 (89%)

 

 Present

95 (12%)

37 (11%)

 
  1. aWilcoxon’s rank-sum test.